The Use of ATP-MgCl2 in the Treatment of Injury and Shock.
Abstract
In conscious rate and primates, bolus infusion of the entire efficacious dose of ATP-MgCl2 transiently decrease mean blood pressure but there were no long term side effects and there were no mortalities. Moreover, daily administration of the entire efficacious dose of ATP-MgCl2 for a period of three months in rats did not produce any mortality or adverse side effects. ATP-MgCl2 was approved for clinical studies by the Food and Drug Administration of the U.S. Army's and our Human Investigation Committee.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 31, 1983
- Accession Number
- ADA148651
Entities
People
- A. E. Baue
- I. H. Chaudry
Organizations
- Yale University